149 related articles for article (PubMed ID: 22876949)
1. Chalcones in cancer: understanding their role in terms of QSAR. II part.
Repanas A; Katsori AM; Hadjipavlou-Litina D
Mini Rev Med Chem; 2013 Jun; 13(7):952-70. PubMed ID: 22876949
[TBL] [Abstract][Full Text] [Related]
2. Chalcones in cancer: understanding their role in terms of QSAR.
Katsori AM; Hadjipavlou-Litina D
Curr Med Chem; 2009; 16(9):1062-81. PubMed ID: 19275612
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and QSAR study of 2'-hydroxy-4'-alkoxy chalcone derivatives that exert cytotoxic activity by the mitochondrial apoptotic pathway.
Marquina S; Maldonado-Santiago M; Sánchez-Carranza JN; Antúnez-Mojica M; González-Maya L; Razo-Hernández RS; Alvarez L
Bioorg Med Chem; 2019 Jan; 27(1):43-54. PubMed ID: 30482548
[TBL] [Abstract][Full Text] [Related]
4. Lipoxygenase inhibitors: a comparative QSAR study review and evaluation of new QSARs.
Pontiki E; Hadjipavlou-Litina D
Med Res Rev; 2008 Jan; 28(1):39-117. PubMed ID: 17191217
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of indolyl chalcones as antitumor agents.
Kumar D; Kumar NM; Akamatsu K; Kusaka E; Harada H; Ito T
Bioorg Med Chem Lett; 2010 Jul; 20(13):3916-9. PubMed ID: 20627724
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and structure-activity relationship studies of furan-ring fused chalcones as antiproliferative agents.
Saito Y; Kishimoto M; Yoshizawa Y; Kawaii S
Anticancer Res; 2015 Feb; 35(2):811-7. PubMed ID: 25667461
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Multifunctional Hybrid Analogs for Stilbenes, Chalcones and Flavanones.
Cagir A; Odaci B; Varol M; Akcok I; Okur O; Koparal AT
Anticancer Agents Med Chem; 2018 Feb; 17(14):1915-1923. PubMed ID: 28554313
[TBL] [Abstract][Full Text] [Related]
8. Recent progress in therapeutic applications of chalcones.
Katsori AM; Hadjipavlou-Litina D
Expert Opin Ther Pat; 2011 Oct; 21(10):1575-96. PubMed ID: 21711087
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic activity of substituted chalcones in terms of molecular electronic properties.
Kupcewicz B; Jarzęcki AA; Małecka M; Krajewska U; Rozalski M
Bioorg Med Chem Lett; 2014 Sep; 24(17):4260-5. PubMed ID: 25091929
[TBL] [Abstract][Full Text] [Related]
10. QSAR of Chalcones Utilizing Theoretical Molecular Descriptors.
Nandi S; Bagchi MC
Curr Comput Aided Drug Des; 2015; 11(2):184-93. PubMed ID: 26135340
[TBL] [Abstract][Full Text] [Related]
11. Antimitotic and antiproliferative activities of chalcones: forward structure-activity relationship.
Boumendjel A; Boccard J; Carrupt PA; Nicolle E; Blanc M; Geze A; Choisnard L; Wouessidjewe D; Matera EL; Dumontet C
J Med Chem; 2008 Apr; 51(7):2307-10. PubMed ID: 18293907
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and topoisomerases inhibitory activity of heteroaromatic chalcones.
Jeon KH; Yu HB; Kwak SY; Kwon Y; Na Y
Bioorg Med Chem; 2016 Nov; 24(22):5921-5928. PubMed ID: 27707625
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of novel β-carboline based chalcones with high cytotoxic activity against breast cancer cells.
Chauhan SS; Singh AK; Meena S; Lohani M; Singh A; Arya RK; Cheruvu SH; Sarkar J; Gayen JR; Datta D; Chauhan PM
Bioorg Med Chem Lett; 2014 Jul; 24(13):2820-4. PubMed ID: 24844196
[TBL] [Abstract][Full Text] [Related]
14. Chalcones with electron-withdrawing and electron-donating substituents: anticancer activity against TRAIL resistant cancer cells, structure-activity relationship analysis and regulation of apoptotic proteins.
Mai CW; Yaeghoobi M; Abd-Rahman N; Kang YB; Pichika MR
Eur J Med Chem; 2014 Apr; 77():378-87. PubMed ID: 24675137
[TBL] [Abstract][Full Text] [Related]
15. Exploitation of new chalcones and 4H-chromenes as agents for cancer treatment.
Pontes O; Costa M; Santos F; Sampaio-Marques B; Dias T; Ludovico P; Baltazar F; Proença F
Eur J Med Chem; 2018 Sep; 157():101-114. PubMed ID: 30081238
[TBL] [Abstract][Full Text] [Related]
16. Brine shrimp lethality assay 'an effective prescreen': microwave-assisted synthesis, BSL toxicity and 3DQSAR studies-based designing, docking and antitumor evaluation of potent chalcones.
Nazir S; Ansari FL; Hussain T; Mazhar K; Muazzam AG; Qasmi ZU; Makhmoor T; Noureen H; Mirza B
Pharm Biol; 2013 Sep; 51(9):1091-103. PubMed ID: 23745524
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, anticancer and antioxidant activities of 2,4,5-trimethoxy chalcones and analogues from asaronaldehyde: structure-activity relationship.
Shenvi S; Kumar K; Hatti KS; Rijesh K; Diwakar L; Reddy GC
Eur J Med Chem; 2013 Apr; 62():435-42. PubMed ID: 23395966
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and evaluation of novel isoxazolyl chalcones as potential anticancer agents.
Wan M; Xu L; Hua L; Li A; Li S; Lu W; Pang Y; Cao C; Liu X; Jiao P
Bioorg Chem; 2014 Jun; 54():38-43. PubMed ID: 24747188
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the Fluorescence Properties of 4-Dialkylaminochalcones and Investigation of the Cytotoxic Mechanism of Chalcones.
Zhou B; Jiang P; Lu J; Xing C
Arch Pharm (Weinheim); 2016 Jul; 349(7):539-52. PubMed ID: 27214789
[TBL] [Abstract][Full Text] [Related]
20. Review in quantitative structure activity relationships on lipoxygenase inhibitors.
Eleni P; Dimitra HL
Mini Rev Med Chem; 2003 Aug; 3(5):487-99. PubMed ID: 12769699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
